Skip to main content

What the FDA labels say about taking them together

Insulin glulisine and lithium

Insulin glulisine's FDA label of November 25, 2025 names lithium in its drug interactions section; the lithium labels PlainMeds reads (4) do not name insulin glulisine. The insulin glulisine label: “Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Alcohol, beta-blockers, clonidine, and lithium salts.”

Check it at the source: the insulin glulisine FDA label on DailyMed (effective November 25, 2025); the lithium FDA label on DailyMed (effective December 23, 2025, Glenmark Pharmaceuticals Inc., USA).

What does the insulin glulisine label say about lithium?

Insulin glulisine label, drug interactions

Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Alcohol, beta-blockers, clonidine, and lithium salts.

Source: FDA drug label (Apidra), sanofi-aventis U.S. LLC, effective November 25, 2025 (SPL set e7af6a7a-8046-4fb4-9979-4ec4230b23aa), via openFDA; the full label on DailyMed

What does the lithium label say about insulin glulisine?

Lithium's label (effective December 23, 2025) and its 3 other brand-application labels do not name insulin glulisine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lithium Carbonate), Glenmark Pharmaceuticals Inc., USA, effective December 23, 2025 (SPL set 63b3790f-a9b5-47f4-bae1-ddf8b43c13c1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Insulin glulisine generic labelers
24Lithium generic labelers
Insulin glulisineLithium
Labeled forType 2 diabetes, Type 1 diabetesBipolar disorder
Boxed warningNoYes
Pharmacy cost (NADAC)$8.16 per mL 100 unit/mL vial$0.104 per capsule 300 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?